SAN DIEGO, March 28, 2024 (GLOBE NEWSWIRE) -- Robbins Geller Rudman & Dowd LLP announces that the bluebird bio class action lawsuit seeks to represent purchasers or acquirers of bluebird bio, Inc. (NASDAQ:BLUE) common stock between April 24, 2023 and December 8, 2023, inclusive (the "Class Period"). Captioned Gill v. bluebird bio, Inc., No. 24-cv-10803 (D. Mass.), the bluebird bio class action lawsuit charges bluebird bio and certain of bluebird bio's top executives with violations of the Securities Exchange Act of 1934.
If you suffered substantial losses and wish to serve as lead plaintiff of the bluebird bio class action lawsuit, please provide your information here:
https://www.rgrdlaw.com/cases-bluebird-bio-inc-class-action-lawsuit-blue.html
You can also contact attorneys J.C. Sanchez or Jennifer N. Caringal of Robbins Geller by calling 800/449-4900 or via e-mail at info@rgrdlaw.com.
CASE ALLEGATIONS: bluebird bio is a biotechnology company that researches, develops, and commercializes gene therapies for severe genetic diseases. According to the complaint, on April 24, 2023, defendants announced submission of its Biologics License Application (BLA) to the U.S. Food and Drug Administration ("FDA") for lovotibeglogene autotemcel ("lovo-cel") gene therapy in patients with sickle cell disease (SCD) ages 12 and older who have a history of vaso-occlusive events.
The bluebird bio class action lawsuit alleges ...